Nan Shan Life Insurance’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Nan Shan Life Insurance’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.3M	Sell	77,701 -60,910	-44%	-$8.23M	0.39%	58
2026 Q1	$17.7M	Buy	138,611 +78,347	+130%	+$9.78M	0.64%	49
2025 Q4	$7.35M	Hold	60,264	–	–	0.23%	65
2025 Q3	$6.04M	Sell	60,264 -1,200	-2%	-$108K	0.13%	90
2025 Q2	$5.1M	Sell	61,464 -3,400	-5%	-$271K	0.11%	96
2025 Q1	$5.26M	Hold	64,864	–	–	0.12%	93
2024 Q4	$5.84M	Hold	64,864	–	–	0.14%	88
2024 Q3	$6.41M	Hold	64,864	–	–	0.15%	76
2024 Q2	$6.01M	Sell	64,864 -160	-0.2%	-$14.3K	0.14%	86
2024 Q1	$6.17M	Sell	65,024 -3,880	-6%	-$360K	0.15%	86
2023 Q4	$6.15M	Sell	68,904 -6,850	-9%	-$509K	0.15%	81
2023 Q3	$5.53M	Sell	75,754 -2,400	-3%	-$192K	0.15%	79
2023 Q2	$6.5M	Sell	78,154 -4,400	-5%	-$368K	0.16%	84
2023 Q1	$6.29M	Sell	82,554 -3,738	-4%	-$310K	0.15%	84
2022 Q4	$7.16M	Sell	86,292 -2,700	-3%	-$219K	0.2%	75
2022 Q3	$7.06M	Buy	88,992 +2,600	+3%	+$219K	0.17%	81
2022 Q2	$6.42M	Buy	86,392 +2,238	+3%	+$168K	0.13%	85
2022 Q1	$7.56M	Sell	84,154 -868	-1%	-$80.2K	0.13%	81
2021 Q4	$9.52M	Hold	85,022	–	–	0.14%	86
2021 Q3	$10.7M	Hold	85,022	–	–	0.18%	86
2021 Q2	$11.5M	Buy	85,022 +33,200	+64%	+$4.36M	0.19%	89
2021 Q1	$7.03M	Buy	51,822 +9,822	+23%	+$1.47M	0.14%	104
2020 Q4	$5.91M	Sell	42,000 -12,226	-23%	-$1.57M	0.12%	108
2020 Q3	$6.04M	Buy	+54,226	New	+$6.08M	0.16%	90
2020 Q2	–	Sell	-12,300	Closed	-$953K	–	116
2020 Q1	$953K	Hold	12,300	–	–	0.03%	91
2019 Q4	$1.17M	Sell	12,300 -3,051	-20%	-$264K	0.04%	86
2019 Q3	$1.17M	Hold	15,351	–	–	0.03%	83
2019 Q2	$1.35M	Hold	15,351	–	–	0.03%	88
2019 Q1	$1.39M	Hold	15,351	–	–	0.03%	99
2018 Q4	$1.1M	Sell	15,351 -4,900	-24%	-$395K	0.03%	103
2018 Q3	$1.94M	Sell	20,251 -10,049	-33%	-$974K	0.04%	99
2018 Q2	$2.88M	Sell	30,300 -39,900	-57%	-$3.67M	0.07%	89
2018 Q1	$6.16M	Buy	+70,200	New	+$6.41M	0.13%	83

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Nan Shan Life Insurance's XBI Position: Q2 2026 in Review

Nan Shan Life Insurance reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 44% in Q2 2026, selling an estimated $8.23M and leaving 77,701 shares worth $12.3M. The position accounts for 0.39% of the portfolio, ranked #58.

Nan Shan Life Insurance first reported a position in XBI in Q1 2018 and has held it in 33 quarters since. The position peaked at $17.7M in Q1 2026. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Nan Shan Life Insurance held 77,701 shares of State Street SPDR S&P Biotech ETF worth $12.3M as of Q2 2026.
Nan Shan Life Insurance sold 60,910 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $8.23M.
State Street SPDR S&P Biotech ETF made up 0.39% of Nan Shan Life Insurance's portfolio in Q2 2026, its #58 holding.
Nan Shan Life Insurance first reported a position in State Street SPDR S&P Biotech ETF in Q1 2018 and has held it in 33 quarters since.
Nan Shan Life Insurance's State Street SPDR S&P Biotech ETF position peaked at $17.7M in Q1 2026.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Nan Shan Life Insurance's 13F filing for Q2 2026, filed 14 Aug 2026.